Table 1 Clinical characteristics of active surveillance candidates in biopsy cohort
Variables | Summary statistics |
|---|---|
No. patients | 266 |
Age, year | |
Median (Q1, Q3) | 62 (58–67) |
Race, n (%) | |
African American | 10 (3.8) |
Caucasian | 65 (24.4) |
Other | 43 (16.2) |
Unavailable | 148 (55.6) |
Biopsy stage, n (%) | |
cT1 | 225 (84.6) |
cT2 | 41 (15.4) |
Biopsy Grade Group, n (%) | |
Grade 1 | 201 (75.6) |
Grade 2 | 65 (24.4) |
% positive biopsy cores | |
Median (Q1, Q3) | 30 (23.7, 40; NA = 2) |
PSA at enrollment, ng/mL | |
Median (Q1, Q3) | 5.4 (4.16, 7.19) |
NCCN, n (%) | |
Low | 172 (64.7) |
Favorable Intermediate | 94 (35.3) |
Categorical CAPRA, n (%) | |
Low | 186 (69.9) |
Int | 76 (28.6) |
Unavailable | 4 (1.5) |
Time from biopsy to RP, month | |
Median (Q1, Q3) | 2.2 (1.35, 3.63) |
RP stage, n (%) | |
pT2c or less | 190 (71.4) |
pT3a | 71 (26.7) |
pT3b | 5 (1.9) |
RP Grade Group, n (%) | |
Grade 1 | 94 (35.3) |
Grade 2 | 144 (54.1) |
Grade 3 | 23 (8.6) |
Grade 4 | 4 (1.5) |
Grade 5 | 1 (0.4) |
Positive surgical margins, n (%) | |
Present | 58 (21.8) |
Absent | 208 (78.2) |
Lymph node invasion, n (%) | |
Present | 3 (1.1) |
Absent | 263 (98.9) |
Follow-up for censored patients, year | |
Median (Q1, Q3) | 5.32 (2.36, 9.22) |
